
SLXN
Healthcare · Biotechnology · $1.3M market cap
$1.98-0.68 (-25.6%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +93.2% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | — | -13.70 | — |
| Aug 14, 2026 | Before the open | -2.12 | -5.17 | -143.9% |
| May 15, 2026 | After the close | -12.90 | -8.50 | +34.1% |
| Mar 18, 2026 | Time not confirmed | -11.20 | -14.11 | -26.0% |
| Nov 12, 2025 | Before the open | -34.00 | -28.80 | +15.3% |
| Aug 7, 2025 | After the close | -0.21 | -4.32 | -1956.7% |
| May 13, 2025 | After the close | — | -0.26 | — |
| Mar 18, 2025 | After the close | -147.00 | -3114.00 | -2018.4% |
| Nov 14, 2024 | Before the open | -148.50 | -2740.50 | -1745.5% |
| Aug 13, 2024 | Before the open | — | -0.03 | — |
| May 15, 2024 | After the close | — | -0.05 | — |
| Mar 31, 2023 | Time not confirmed | — | 0.03 | — |
| Nov 14, 2022 | Time not confirmed | — | 0.02 |
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead…
| — |
| Aug 15, 2022 | Time not confirmed | — | 0.39 | — |
| May 23, 2022 | Time not confirmed | — | -0.02 | — |
| Mar 31, 2022 | Time not confirmed | — | -0.02 | — |
| Nov 9, 2021 | Time not confirmed | — | -0.02 | — |
| Aug 16, 2021 | Time not confirmed | — | -0.01 | — |
| May 25, 2021 | Time not confirmed | — | -0.01 | — |